| PBPK models for CYP3A4 and P‐gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin N Hanke, S Frechen, D Moj, H Britz, T Eissing, T Wendl, T Lehr CPT: pharmacometrics & systems pharmacology 7 (10), 647-659, 2018 | 125 | 2018 |
| Ca2+ transients activate calcineurin/NFATc1 and initiate fast-to-slow transformation in a primary skeletal muscle culture HP Kubis, N Hanke, RJ Scheibe, JD Meissner, G Gros American Journal of Physiology-Cell Physiology 285 (1), C56-C63, 2003 | 116 | 2003 |
| Population nutrikinetics of green tea extract C Scholl, A Lepper, T Lehr, N Hanke, KL Schneider, J Brockmöller, ... PLoS One 13 (2), e0193074, 2018 | 73 | 2018 |
| Accumulation and nuclear import of HIF1 alpha during high and low oxygen concentration in skeletal muscle cells in primary culture HP Kubis, N Hanke, RJ Scheibe, G Gros Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1745 (2), 187-195, 2005 | 67 | 2005 |
| Cushing’s syndrome: Development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl) pyridine type J Emmerich, Q Hu, N Hanke, RW Hartmann Journal of medicinal chemistry 56 (15), 6022-6032, 2013 | 59 | 2013 |
| Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice O Adam, C Zimmer, N Hanke, RW Hartmann, B Klemmer, M Böhm, ... Journal of molecular and cellular cardiology 85, 140-150, 2015 | 51 | 2015 |
| Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug–drug interactions and co-medication regimens D Moj, N Hanke, H Britz, S Frechen, T Kanacher, T Wendl, WE Haefeli, ... The AAPS journal 19, 298-312, 2017 | 45 | 2017 |
| Design, synthesis, and structure–activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors MG Ferlin, D Carta, R Bortolozzi, R Ghodsi, A Chimento, V Pezzi, S Moro, ... Journal of Medicinal Chemistry 56 (19), 7536-7551, 2013 | 43 | 2013 |
| Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network … D Türk, N Hanke, S Wolf, S Frechen, T Eissing, T Wendl, M Schwab, ... Clinical Pharmacokinetics 58, 1595-1607, 2019 | 38 | 2019 |
| A comprehensive whole-body physiologically based pharmacokinetic drug–drug–gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals N Hanke, D Türk, D Selzer, N Ishiguro, T Ebner, S Wiebe, F Müller, ... Clinical Pharmacokinetics 59, 1419-1431, 2020 | 34 | 2020 |
| Physiologically‐Based Pharmacokinetic Models for CYP 1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam H Britz, N Hanke, AK Volz, O Spigset, M Schwab, T Eissing, T Wendl, ... CPT: pharmacometrics & systems pharmacology 8 (5), 296-307, 2019 | 33 | 2019 |
| Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing W Zhu, Q Hu, N Hanke, CJ van Koppen, RW Hartmann Journal of Medicinal Chemistry 57 (18), 7811-7817, 2014 | 33 | 2014 |
| Pharmacokinetics of the CYP3A4 and CYP2B6 inducer carbamazepine and its drug–drug interaction potential: a physiologically based pharmacokinetic modeling approach LM Fuhr, FZ Marok, N Hanke, D Selzer, T Lehr Pharmaceutics 13 (2), 270, 2021 | 32 | 2021 |
| Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4′-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β … A Stefanachi, N Hanke, L Pisani, F Leonetti, O Nicolotti, M Catto, ... European journal of medicinal chemistry 89, 106-114, 2015 | 27 | 2015 |
| A comprehensive whole-body physiologically based pharmacokinetic model of dabigatran etexilate, dabigatran and dabigatran glucuronide in healthy adults and renally impaired … D Moj, H Maas, A Schaeftlein, N Hanke, JD Gómez-Mantilla, T Lehr Clinical pharmacokinetics 58, 1577-1593, 2019 | 23 | 2019 |
| Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities E Perspicace, L Cozzoli, EM Gargano, N Hanke, A Carotti, RW Hartmann, ... European Journal of Medicinal Chemistry 83, 317-337, 2014 | 22 | 2014 |
| Gene regulation mediating fiber-type transformation in skeletal muscle cells is partly glucose-and ChREBP-dependent N Hanke, RJ Scheibe, G Manukjan, D Ewers, PK Umeda, KC Chang, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1813 (3), 377-389, 2011 | 22 | 2011 |
| A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin—integration of in vitro results, Phase I and Phase II … N Hanke, M Teifel, D Moj, JG Wojtyniak, H Britz, B Aicher, H Sindermann, ... Cancer chemotherapy and pharmacology 81, 291-304, 2018 | 21 | 2018 |
| Metabolic stability optimization and metabolite identification of 2, 5-thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors EM Gargano, E Perspicace, N Hanke, A Carotti, S Marchais-Oberwinkler, ... European journal of medicinal chemistry 87, 203-219, 2014 | 19 | 2014 |
| Translational PBPK modeling of the protein therapeutic and CD95L inhibitor asunercept to develop dose recommendations for its first use in pediatric glioblastoma patients N Hanke, C Kunz, M Thiemann, H Fricke, T Lehr pharmaceutics 11 (4), 152, 2019 | 18 | 2019 |
Thorsten LehrUniversität des SaarlandesVerified email at mx.uni-saarland.de
